AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).

Coronary Artery Disease Clinical Trial

— FLAVOUR  

Official title:

A 12-week, Randomized, Single-blind, Placebo-controlled, Multi-centre, Parallel Group, Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 After 4 and 12-weeks of Treatment in Patients With Coronary Artery Disease (CAD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03317002
• Other study ID #: D7550C00003
• Status: Completed
• Phase: Phase 2
• Start date: October 30, 2017
• Est. completion date: April 8, 2020

Study information

• Verified date: June 2021
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, single-blind, placebo-controlled, parallel-group, multicentre study in patients with CAD. The study will be conducted at approximately 10 centres in 3 countries. Approximately 138 CAD patients will be randomized to AZD5718 or placebo (treatment duration 12 weeks).

Description:

This is a randomized, single-blind, placebo-controlled, parallel-group, multicentre study in patients with CAD. The study will be conducted at approximately 10 centres in 3 countries (Denmark, Finland and Sweden). Patients suitable for the study will be identified and screened for eligibility after being hospitalized for Acute Coronary Syndrome (ACS) (Visit 1) comprising ST Elevation Myocardial Infarction (STEMI) or Non-ST Elevation Myocardial Infarction (non-STEMI). At Visit 1, after signing informed consent, study measurements will take place at days 1, 2, 3 and 5 post ACS, where feasible. It is planned that approximately 138 CAD patients will be randomized to ensure at least 66 evaluable patients receiving AZD5718 Dose B or placebo are included with 12 weeks treatment. For supporting dose selection in future studies, a treatment arm with 28 randomized patients receiving AZD5718 Dose A is included in the study. The study was originally designed to be a 4-week study and was amended to be a 12-week study. Therefore, the total number of patients is greater than required for a 12 weeks study (about 100), since some patients will only have 4 weeks of treatment. An evaluable patient is defined as a patient with a valid Coronary Flow Velocity Reserve (CFVR) measurement at Visit 2 and one post baseline visit as judged by the CFVR Core lab. On Day 1 (Visit 2), 7 to 28 days after the ACS event, patients willing to participate in the study will complete the screening procedure and, if eligible, be randomized. Treatment duration will be 12 weeks. During the treatment phase, patients will come in to the clinic for study measurements at 2 weeks (visit 3), 4 weeks (visit 4), 8 weeks (visit 4b) and 12 weeks (visit 4c). A follow-up visit (Visit 5) will be performed at 4 weeks (±4 days) after last dose in order to ensure safety and well-being of the patients

Recruitment information / eligibility

• Status: Completed
• Enrollment: 129
• Est. completion date: April 8, 2020
• Est. primary completion date: April 8, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Males and females of non-childbearing potential
• Age =18 to =75
• Body Mass Index (BMI) =18 to =35 kg/m2
• CAD patients, here defined as:

ACS 7-28 days prior to study randomization (ACS defined as STEMI, non STEMI event documented by Electrocardiogram (ECG), cardiac enzymes [troponin] and angiogram) Provision of signed and dated, written informed consent prior to any study specific procedures

Exclusion Criteria:

• Uncontrolled Type 1 or Type 2 diabetes defined as haemoglobin A1c (HbA1c) Diabetes
• Control and Complications Trial (DCCT)> 9% or International Federation of Clinical Chemistry (IFCC) >74.9 mmol/mol
• Patients with atrial fibrillation (chronic or current) or history of ventricular tachycardia requiring therapy for termination, or symptomatic sustained ventricular tachycardia or sick sinus syndrome or Atrioventricular blockage degree 2-3
• Prior coronary artery by-pass graft (Coronary artery bypass grafting) to Left Anterior Descending artery (LAD)
• Left ventricle ejection fraction < 30%
• Unacceptable level of angina despite maximal medical therapy or unstable angina at entry
• Canadian Cardiovascular Society (CCS) = 3 (Visit 1 or Visit 2)
• Stroke within the previous 6 months from ACS or ongoing treatment with Persantin or Asasantin
• Chronic use of anticoagulants on therapeutic dose (not including thrombosis prophylaxis) during the study
• Planned additional cardiac intervention (e.g., Percutaneous coronary intervention (PCI), Coronary artery bypass grafting (CABG) within next 6 months
• New York Heart Association (NYHA) class III-IV heart failure or decompensated heart failure at discharge or hospitalization for exacerbation of chronic heart failure within the previous 3 months from ACS
• Previously known severe renal disease (Chronic Kidney Disease (CKD) stage 4 or 5) or previously known creatinine clearance calculated by Cockcroft Gault equation <30 ml/min*m2
• Known allergy to adenosine and mannitol, or experience of previous adverse effects of adenosine stress testing.
• Participation in another interventional clinical study with an investigational pharmaceutical product during the last 3 months also including drug eluting stents.

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Drug:
• AZD5718
Oral dose of AZD5718 (tablet)
• AZD5718
Oral dose of AZD5718 (tablet)
• Placebo
Matching placebo (tablet)

Locations

Country	Name	City	State
Denmark	Research Site	Aarhus
Denmark	Research Site	Frederiksberg
Denmark	Research Site	Odense C
Finland	Research Site	Kuopio
Finland	Research Site	Turku
Sweden	Research Site	Göteborg
Sweden	Research Site	Lund
Sweden	Research Site	Stockholm
Sweden	Research Site	Uppsala

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Countries where clinical trial is conducted

Denmark,  Finland,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Creatinine-normalized u-LTE4 at Week 4	Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine	Baseline and 4 weeks
Secondary	Change From Baseline in Creatinine-normalized u-LTE4 at Week 12	Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine	Baseline and 12 weeks
Secondary	Change From Baseline in CFVR at Week 12	CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)	Baseline and 12 weeks
Secondary	Change From Baseline in CFVR at Week 4	CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)	Baseline and 4 weeks
Secondary	Summary of Plasma Concentrations of AZD5718		16 weeks
Secondary	Change From Baseline in LAD Hypereamic Flow at 4 Weeks	LAD=Left Anterior Descending	Baseline and 4 weeks
Secondary	Change From Baseline in LVEF at 4 Weeks	LVEF=Left Ventricular Ejection Fraction	Baseline and 4 weeks
Secondary	Change From Baseline in LV Longitudinal Early Diastolic Strain Rate at 4 Weeks	LV=Left Ventricular	Baseline and 4 weeks
Secondary	Change From Baseline in LV-GLS at Rest at Week 4	LV-GLS = Left Ventricular Global Longitudinal Strain	Baseline and 4 weeks
Secondary	Change From Baseline in LV-GCS at Rest at Week 4	LV-GCS = Left Ventricular Global Circumferential Strain	Baseline and 4 weeks
Secondary	Change From Baseline in LAD Resting Mean Diastolic Flow Velocity at 4 Weeks	LAD=Left Anterior Descending	Baseline and 4 weeks

External Links

•   redacted Clinical Study Protocol
•   redacted Statistical Analysis Plan